Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000-2012
- PMID: 25636927
- DOI: 10.1016/j.cmi.2014.07.003
Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000-2012
Abstract
Clostridium difficile infection is one of the most common nosocomial infections. Among other alternatives to standard treatment with vancomycin for recurrent infection are faecal microbiota transplantation and rectal bacteriotherapy with a fixed mixture of intestinal bacterial strains isolated from faeces of healthy persons to mimic a theoretical normal microflora. Developed by Dr. Tvede and Dr. Rask-Madsen, the latter method has been in use for selected patients during the last 25 years in Denmark. In this study we reviewed the medical records of patients treated with rectal bacteriotherapy for relapsing C. difficile in Denmark, 2000-2012. The primary end point was recurrent diarrhoea within 30 days after treatment. A total of 55 patients were included in this case series. Thirty-five patients (64%) had no recurrence within 30 days of bacteriotherapy. Patients with recurrence tended to be older (75.8 years vs. 61.3 years; p 0.26), and more often have preexisting gastrointestinal illness and longer duration of time from the first CDI to bacteriotherapy (221.6 days vs. 175.3 days; p 0.18). Treatment success was 80% in the subgroup of patients with no known gastrointestinal illness and first C. difficile episode less than 6 months before bacteriotherapy. The most common adverse events were abdominal pain (10.9%) and worsening diarrhoea (4.3%). One patient was hospitalized 10 days after treatment with appendicitis, fever, and Escherichia coli bacteremia. The results from this study indicate that rectal bacteriotherapy is a viable alternative to faecal microbiota transplantation in patients with relapsing C. difficile-associated diarrhoea.
Keywords: Case series; faecal bacteriotherapy; recurrent Clostridium difficile.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients.Scand J Infect Dis. 2014 Feb;46(2):89-97. doi: 10.3109/00365548.2013.858181. Epub 2013 Dec 20. Scand J Infect Dis. 2014. PMID: 24354958
-
Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results.J Clin Gastroenterol. 2012 Feb;46(2):145-9. doi: 10.1097/MCG.0b013e318234570b. J Clin Gastroenterol. 2012. PMID: 22157239
-
Faecal microbiota transplantation for Clostridium difficile infection.Int J Clin Pract. 2014 Mar;68(3):363-8. doi: 10.1111/ijcp.12320. Epub 2013 Dec 22. Int J Clin Pract. 2014. PMID: 24372725 Review.
-
[Fecal bacteriotherapy for the treatment of recurrent Clostridium difficile colitis used in the Clinic of Infectious Diseases of the University Hospital Brno in 2010-2014 - a prospective study].Epidemiol Mikrobiol Imunol. 2015 Oct;64(4):232-5. Epidemiol Mikrobiol Imunol. 2015. PMID: 26795227 Czech.
-
Fecal bacteriotherapy for recurrent Clostridium difficile infection.Anaerobe. 2009 Dec;15(6):285-9. doi: 10.1016/j.anaerobe.2009.09.007. Epub 2009 Sep 22. Anaerobe. 2009. PMID: 19778623 Review.
Cited by
-
The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study.Cells. 2022 Oct 18;11(20):3272. doi: 10.3390/cells11203272. Cells. 2022. PMID: 36291139 Free PMC article.
-
Banking feces: a new frontier for public blood banks?Transfusion. 2019 Sep;59(9):2776-2782. doi: 10.1111/trf.15422. Epub 2019 Jun 26. Transfusion. 2019. PMID: 31241182 Free PMC article.
-
Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection.PLoS One. 2021 Apr 9;16(4):e0249861. doi: 10.1371/journal.pone.0249861. eCollection 2021. PLoS One. 2021. PMID: 33836037 Free PMC article.
-
Innate Immune Defenses Mediated by Two ILC Subsets Are Critical for Protection against Acute Clostridium difficile Infection.Cell Host Microbe. 2015 Jul 8;18(1):27-37. doi: 10.1016/j.chom.2015.06.011. Cell Host Microbe. 2015. PMID: 26159718 Free PMC article.
-
Knowledge, attitudes, ethical and social perspectives towards fecal microbiota transplantation (FMT) among Jordanian healthcare providers.BMC Med Ethics. 2021 Feb 27;22(1):19. doi: 10.1186/s12910-021-00587-6. BMC Med Ethics. 2021. PMID: 33639935 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical